This document is a publication of a US patent application (US20260085105A1) filed by Amgen Inc. The application describes recombinant T-cell receptors (TCRs) engineered to recognize specific MAGE-A4-derived peptides when presented by HLA-A*0201, with the aim of activating recombinant T cells. The inventors have screened these TCRs for cross-reactivity with similar peptides found in normal cells and for alloreactivity.

As this is a patent application, it does not impose immediate regulatory obligations or compliance deadlines on entities. However, it signifies potential future intellectual property and product development in the field of cancer immunotherapy. Companies operating in the pharmaceutical and biotechnology sectors, particularly those involved in T-cell therapy or cancer treatment, should be aware of this filing as it may impact their research and development strategies or patent landscape.